Last updated 3 days ago
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
3501 patients around the world
Available in Puerto Rico, Argentina, United States
Amgen
4Research sites
3501Patients around the world
This study is for people with
Obesity
Requirements for the patient
To 99 Years
All Gender
Medical requirements
- Age ≥ 18 years.Body mass index ≥ 30 kg/m2 or ≥27 kg/m² to < 30 kg/m2 with at least 1 of the following weight-related comorbidities: hypertension, dyslipidemia, history of obstructive sleep apnea, history of cardiovascular disease, history of metabolic dysfunction-associated steatotic liver disease (MASLD) or Metabolic Dysfunction-Associated Steatohepatitis (MASH).History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.
- Type 1 or Typ2 diabetes mellitus.Obesity induced by other endocrinologic disorders.Self-reported change in body weight > 5 kg within 90 days before screening.Family (first-degree relative[s]) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2.History of chronic pancreatitis or history of acute pancreatitis within 180 days before screening.History of unstable major depressive disorder (MDD) or other severe psychiatric disorder within 2 years before screening.Lifetime history of suicide attempt.
Sites
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Recruiting
Ponce Medical School Foundation Inc
Recruiting
Puerto Rico Medical Research Center
Recruiting
Latin Clinical Trial Center - Puerto Rico
Recruiting
StudyMARITIME-1
SponsorAmgen
Study typeInterventional
Conditions
Obesity
Requirements
To 99 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06858839
